-
Mashup Score: 0
Capivasertib plus abiraterone and ADT improved rPFS in PTEN-deficient metastatic hormone-sensitive prostate cancer.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 51Decipher® in mHSPC: Guiding Risk Assessment and Treatment Intensification - Gerhardt Attard - 19 day(s) ago
Nicholas James and Gerhardt Attard discuss findings from the STAMPEDE trial, focusing on molecular profiling of prostate cancer tumors. They explore the use of the Decipher® genomic classifier as a prognostic and predictive tool for treatment decisions in metastatic prostate cancer. The conversation covers the test’s ability to identify patients who are likely to benefit from abiraterone and,…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
Decipher® in #mHSPC: Guiding risk assessment and treatment intensification. @AttardLab @ucl joins @Prof_Nick_James @ICR_London discussing findings from the #STAMPEDE trial, focusing on molecular profiling of prostate cancer tumors. #FullVideo on UroToday > https://t.co/rY9qSTqS13… https://t.co/GCfiSkozDB https://t.co/q3zMDsfnYz
-
-
Mashup Score: 3
The supplemental new drug application (sNDA) is based on results from a phase 3 trial that enrolled patients with metastatic hormone-sensitive prostate cancer (mHSPC).
Source: www.pharmacytimes.comCategories: General Medicine News, General Journals & SocietTweet-
#FDA News: The FDA has accepted a supplemental new drug application for darolutamide in combination with an ADT for the treatment of patients with metastatic hormone-sensitive #prostate cancer, based on positive trial clinical results. Read more: https://t.co/CP9EsuJs9b
-
-
Mashup Score: 2Coordinating Complex Care in High-Volume mHSPC Through Multidisciplinary Communication - Jonathan Henderson & Sunil Kakadia - 21 day(s) ago
Alicia Morgans convenes a discussion on managing high-volume metastatic hormone-sensitive prostate cancer, bridging the practices of urology and medical oncology with Jonathan Henderson and Sunil Kakadia, a medical oncologist from Genesis Oncology. They emphasize the importance of collaborative care in treating complex cases, like a patient presenting with high PSA levels, highlighting the…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
Coordinating complex care in high-volume #mHSPC through multidisciplinary communication. Jonathan Henderson, MD @ArUrology & Sunil Kakadia, MD, MPH, FACP join @CaPsurvivorship @DanaFarber in this discussion on managing high-volume mHSPC > https://t.co/wB74NwGIJy https://t.co/eirLyGGyql
-
-
Mashup Score: 5
Alicia Morgans speaks with Mary-Ellen Taplin about strategies for managing metastatic hormone-sensitive prostate cancer (mHSPC) patients who do not achieve optimal PSA declines. Dr. Taplin emphasizes that an unfavorable PSA decline is not synonymous with progression and highlights the prognostic value of achieving a PSA nadir below 0.2. She discusses data from various trials, such as SWOG 9346,…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
Escalation strategies for suboptimal PSA decline in #mHSPC. Mary-Ellen Taplin, MD @DanaFarber joins @CaPsurvivorship to discuss managing mHSPC patients who do not achieve optimal PSA declines > https://t.co/tNfpLBly8Y https://t.co/tIYIaWUpyG
-
Capivasertib Plus Abiraterone/ADT Improves rPFS in PTEN-Deficient mHSPC #pcsm #oncology https://t.co/zEqeFfOp3M